secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001193125-25-139950
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Rein Therapeutics pauses US enrollment in Phase 2 RENEW trial due to FDA clinical hold
--------------------------------------------------------------------------------

- FDA placed clinical hold on Phase 2 RENEW trial of LTI-03 on June 10, 2025; US enrollment and dosing paused.
- Rein is working with FDA to address non-clinical requests to resume US enrollment.
- Trial continues with site initiation and patient enrollment in Australia, UK, and Europe.
- No drug-related serious adverse events reported across all LTI-03 studies.
- LTI-03 is a novel Caveolin-1-related peptide for idiopathic pulmonary fibrosis (IPF).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525139950/0001193125-25-139950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312525139950/d940498d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-139950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer